Nxera Pharma Co Ltd (SOLTF) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Time has come, so we will now begin the financial results briefing of Nexera Pharma for the first half of FY 2025. Thank you very much for taking time after a busy schedule to join us today. I'm Nomura, CFO, and I will be the moderator. Today we have Chris Cargill, CEO, and Dr. Matt Barnes, CSO and President of Nexera UK. Simultaneous interpretation is provided. Please click on the language selection icon and select either Japanese or English. If you choose off, you will hear the speaker's original voice. Today, we will explain, as always, the progress of our business using the material in the first half, followed by Q&A session in the second half. The presentation materials will be shown on the screen and are also available on our website. If you want a copy, please enter from the news tab on the website on the left side and access the financial results material. For the Q&A session in the second half, institutional investors, analysts, and members of the media are welcome to raise your hands and ask questions. For all others, please submit your questions via the Q&A button. Questions can be submitted any time during the webinar and will be answered as time permits during the Q&A session. So we will start the briefing. Chris will first explain the operational highlights, then I will explain the first half results and Japan and a pack commercial business, followed by matt on r&d progress, mainly in the UK and, finally, Chris will explain our fyi 2025 goals and medium to long term objectives, please do to page five of the presentation, Chris the floor is yours. Fantastic. Thank you, Nomura-san. And good afternoon, everyone. I'm Chris Cargill, CEO of Nexera Pharma. Thank you for joining us today for our Q2 2025 results presentation. On slide three, I'll begin by walkin...